In:
International Journal of Urology, Wiley, Vol. 21, No. 12 ( 2014-12), p. 1239-1244
Abstract:
To evaluate the safety and efficacy of abiraterone acetate and prednisolone in K orean and T aiwanese patients with metastatic castration‐resistant prostate cancer not responding to docetaxel‐based chemotherapy. Methods In this single‐arm study, 82 metastatic castration‐resistant prostate cancer patients who failed docetaxel‐based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate‐specific antigen decline ≥50% were considered as responding. Results A total of 35 patients (43%) achieved prostate‐specific antigen response (95% confidence interval 32–54). The median time to prostate‐specific antigen progression was 4.7 months (95% confidence interval 3.7–8.3); the median overall survival was 11.8 months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21 nmol/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725 μmol/L (baseline) to 0.080 μmol/L (cycle 4). The most common adverse event was bone pain (20%); grade 3/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%). Conclusions A combination of abiraterone acetate and prednisolone appears to be a favorable second‐line treatment in T aiwanese and K orean patients with advanced metastatic castration‐resistant prostate cancer after failed docetaxel‐based chemotherapy.
Type of Medium:
Online Resource
ISSN:
0919-8172
,
1442-2042
DOI:
10.1111/iju.2014.21.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2009793-1
Permalink